MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

SpringWorks Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

41.69 -5.53

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

40.91

Max

43.7

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-24M

-77M

Pardavimai

12M

62M

Pelnas, tenkantis vienai akcijai

-1.04

Pelno marža

-125.586

Darbuotojai

368

EBITDA

-23M

-80M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+62.5% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-05-01

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-839M

3.3B

Ankstesnė atidarymo kaina

47.22

Ankstesnė uždarymo kaina

41.69

Naujienos nuotaikos

By Acuity

50%

50%

173 / 386 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

SpringWorks Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-02-11 07:03; UTC

Įsigijimai, susijungimai, perėmimai

Germany's Merck in Talks to Buy SpringWorks Therapeutics

2025-02-10 16:38; UTC

Pagrindinės rinkos jėgos
Įsigijimai, susijungimai, perėmimai

SpringWorks Therapeutics Shares Rise on Report it May be Acquired

2025-02-11 10:54; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Germany's Merck Potential Buy of SpringWorks Therapeutics Puts Its Strategy Into Question -- Market Talk

2025-02-11 10:52; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

German Merck's Potential Buy of SpringWorks Therapeutics Holds Profitability Risk -- Market Talk

Akcijų palyginimas

Kainos pokytis

SpringWorks Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

62.5% į viršų

12 mėnesių prognozė

Vidutinis 71.71 USD  62.5%

Aukščiausias 87 USD

Žemiausias 63 USD

Remiantis 7 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines SpringWorks Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

7 ratings

7

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

N/A / 47.505Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bearish Evidence

Vidutinės trukmės periodas

Weak Bullish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

173 / 386 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę SpringWorks Therapeutics Inc

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.